RCC patients present a shift from a type-1-mediated CD4+ T cell response producing interferon gamma (IFNγ) to a type-2 cytokine response, involving interleukins (IL) 4, 5, and 10. The gene discussed is IFNG; the disease is renal cell carcinoma.